Shuttle Pharmaceuticals Announces Public Equity Offering for Expansion

Shuttle Pharmaceuticals Holdings, Inc. ( (SHPH) ) just unveiled an update.

On March 5, 2026, Shuttle Pharmaceuticals priced a public offering of 2,238,800 shares of common stock and pre-funded warrants for 4,761,200 additional shares, raising approximately $3.5 million in gross proceeds, with the transaction closing on March 9, 2026. The financing, arranged on a reasonable best-efforts basis with E.F. Hutton & Co. as exclusive placement agent and subject to short-term lock-up and issuance restrictions, is expected to fund up to $1.5 million in marketing and provide additional working capital, bolstering the company’s resources to commercialize its AI-driven drug discovery platform.

Spark’s Take on SHPH Stock

According to Spark, TipRanks’ AI Analyst, SHPH is a Underperform.

Shuttle Pharmaceuticals Holdings, Inc. faces significant financial challenges with no revenue and ongoing cash burn. Technical indicators show bearish trends, and valuation metrics highlight the company’s unprofitability. While recent corporate activities offer potential strategic benefits, they also add financial strain and governance complexities, leading to an overall low stock score.

To see Spark’s full report on SHPH stock, click here.

More about Shuttle Pharmaceuticals Holdings, Inc.

Shuttle Pharmaceuticals Holdings, Inc., listed on Nasdaq as SHPH and based in Gaithersburg, Md., operates in the pharmaceutical and drug discovery technology sector. The company owns Molecule.ai, an artificial intelligence–driven software platform that supports molecular discovery and early-stage drug development by helping researchers explore chemical space and evaluate molecular ideas more efficiently.

Average Trading Volume: 2,710,192

Technical Sentiment Signal: Sell

Current Market Cap: $3.22M

See more data about SHPH stock on TipRanks’ Stock Analysis page.